Nuvectis Pharma, Inc. (NVCT) reported significantly widened losses for Q3 and the nine months ended September 30, 2025, characteristic of its early-stage clinical development focus.
Financial Performance & Liquidity The 9-month net loss increased to \((19.1M)\) from \((12.8M)\) in 2024, with the Q3 loss reaching \((7.5M)\). Net Loss Per Share (LPS) deteriorated to \((1.01)\) for the 9-month period. Research and Development expenses spiked in Q3, driven by a one-time \(\\)2.0M\( license fee related to an NXP900 milestone. The Accumulated Deficit reached \)$(92.4M)$. Liquidity improved substantially,
...